CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

Number 5: Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions. Number 4: Government price ...

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.